Introduction
The prevalence of knee OA has doubled since the mid 20 th century despite the concerted efforts of the research and pharmaceutical industries over the last 5 decades to develop a therapeutic solution [1] . The global epidemic increase in BMI [2] may well have contributed to this higher incidence of OA [3, 4] through a combined effect of joint overloading and adiposity induced mild inflammation [5] . A Medline literature survey conducted in 2012 on OA and its associated medical costs based on 3 European, 6 North
American and 2 Asian studies [6] showed that the annual cost of topical and oral NSAIDs for the treatment of OA was US$57.38 million. Hip and knee replacement costs exceeded US$1087.43 million and arthroscopic OA surgery US$1.71 million. Indirect lost economic productivity due to OA cost over US$ 4.1 billion, community services expenditure (US$ 5.25 million) and cost estimates for social services US$275 million [6] . A global OA study published in 2014 which examined the impact of knee and hip OA in 291 countries confirmed these major socioeconomic impacts [3] . Despite the pharmaceutical industry largely abandoning investigation into anti-arthritic biotherapeutics there remains a huge need to fully understand and treat OA in all of its complexities. Armed with a better understanding of key disease processes, the research and pharmaceutical communities will be in a better position to finally resolve the therapeutic alleviation of this apparently intractable disease.
The aim of the present study was to examine the susceptibility of fibromodulin (FMOD) and lumican (LUM) to degradation in cartilage development, maturation and pathology. FMOD and LUM are horse-shoe shaped class II members of the leucine rich repeat proteoglycan (SLRP) family [7] . FMOD and LUM are structurally homologous proteins sharing 47% identity in primary structure [8, 9] . Like all class II SLRPs FMOD and LUM contain 12 leucine rich repeat domains (LRRs) which provides them with interactive properties with a number of extracellular matrix (ECM) proteins. Foremost in these interactions which organise tissue form and function is the interaction of FMOD and LUM with type I and type II fibrillar collagens. FMOD and LUM interact with the same binding sites on type I collagen and regulate fibrillogenesis in-vitro [10] . FMOD-deficient mice have collagen fibrils of altered dimensions in tendons, and these mice display OA-like features in their knee articular cartilages [11, 12] . In addition, studies in knock-out mice indicate that LUM and FMOD reciprocally inhibit collagen interactions, through their binding sites on type I collagen [10] .
The increased deposition of LUM in FMOD-deficient mice suggests that LUM binds to nonoccupied FMOD-binding sites in collagen I [10] . FMOD and LUM are not redundant since they do not share functional equivalence in terms of how they organise ECM proteins in connective tissues. In the cornea lumican regulates the small regularly spaced orthogonal collagen fibre arrangements which are essential for optical clarity [13] [14] [15] [16] [17] [18] [19] . In contrast, fibromodulin is more prominent in the limbus and sclera where it stabilises large collagen fibre formation which provide mechanical stability to the eye-ball [15, 20, 21] . Results from FMOD knock-out mice also show that FMOD promotes formation of thick collagen fibres in tendon, whereas LUM forms thin collagen fibres [8] . residues, FMOD contains up to nine sulfated tyrosine residues and LUM two [22, 23] . These are interactive with the heparin-binding proteins FGF-2, TSP-I, MMP-13, the NC4 domain of collagen IX, and IL-10. The tyrosine sulfate residues of FMOD also bind to collagen and promote fibril formation [24] . FMOD also sequesters TGF-β in the ECM and controls its bioavailability, binds C1q and activates the complement system [25] [26] [27] . LUM differs from FMOD in terms of its interactive properties with cells and the cellular responses it elicits.
LUM impedes tumour growth, local invasion, intravasation and extravasation through its MMP-14 inhibitory activity, ability to affect focal adhesions and influence the migration properties and growth of tumour cells through its interactive properties with α2β1 integrin and its inhibitory effects on angiogenesis [28] [29] [30] . LUM also has novel roles in the innate immune response in the regulation of bacterial lipopolysaccharide sensing by Toll-like receptor-4 (TLR-4), in the presentation of bacterial lipopolysaccharide to CD14 and in the host response to this bacterial endotoxin [31] . LUM promotes bacterial phagocytosis [31, 32] and also regulates inflammation in connective tissues [33] .
LUM and FMOD differ in their susceptibilities to degradation by metalloproteinases (MMPs). LUM was recently identified as an inhibitor of MMP-14 [34] and this is considered to contribute to its ability to regulate cell migration [35] and along with its interactive properties with α2β1 integrin to regulate angiogenesis and tumour growth [29] . LUM prevents cleavage of collagen by MMP-13 in-vitro or at least delays this reaction. In contrast to FMOD, LUM is not degraded by MMP-2, 3, 8, 9, 12, 13 [36] . In a study designed to examine the susceptibility of knee articular cartilage ECM components to MMP digestion, pieces of cartilage were used as substrates rather than soluble proteins and digestion was undertaken over 1-21 days. Evidence of proteolysis was determined by sequence identification of unique peptides generated by this procedure using a proteomics type approach [36] . Peptides arising from types I, II, and III collagen, BGN, PRELP, FMOD, fibronectin, DCN, COMP, CILP, mimecan, aggrecan, and LUM were generated using MMP-2, 3, 8, 9, 12, 13, ADAMTS-4 and ADAMTS-5. ADAMTS-4 was the only MMP which degraded LUM releasing two small cleavage peptides, even so the abundance of these peptides was the least of any of the peptides generated in this study. Furthermore, LUM was resistant to degradation by all MMPs examined except MMP-12 which released 3 peptides. In comparison FMOD was extensively degraded by all MMPs tested with as many as 15 peptides generated by ADAMTS-4 and 18 peptides by MMP-12. The tyrosine sulfate rich region of FMOD is also cleaved by MMP-13. MMP-13 also cleaves the α1-IX collagen chain which resides on type II collagen fibrils in-situ (Danfelter et al 2007) . This event precedes enzymatic attack of the type II collagen fibre.
In the present study we immunolocalised FMOD and its MMP-13 cleaved form in foetal human rudiment foot cartilage and in macroscopically normal and fibrillated human knee articular cartilage. In-vitro cleavage of FMOD and LUM by MMP-13 and ADAMTS-4 or -5 were also examined in macroscopically normal cartilage fragments and the cleavage peptides identified by Western blotting using antibodies to epitopes located in the N-and Ctermini. The results obtained indicated that FMOD was degraded by MMP-13 in rudiment cartilage development, stimulated by treatment of knee articular cartilage with IL-1 and
Oncostatin M in-vitro and was evident in pathological knee articular cartilage. In contrast,
we found little evidence of cleavage of LUM by MMPs. The LUM fragmentation patterns we observed in aged human knee articular cartilage were therefore apparently due to another class of proteinase which awaits identification. BMP-1 is one proteinase of interest, BMP-1 processes mimecan/osteoglycin a related SLRP and enhances its ability to regulate collagen fibrillogenesis [37] .
Results
We initially examined the immunolocalisation of FMOD and MMP-13 cleaved FMOD in the developmental phalangeal and metatarsal cartilage rudiments and metatarsal growth plate (Fig 1) . This demonstrated the prominent distribution of full length FMOD in the foot rudiment cartilages associated with normal and hypertrophic chondrocytes (Fig 1a, d, g ).
MMP-13 cleaved FMOD displayed a similar distribution pattern in these tissues but was more prominently produced by the terminal hypertophic chondrocytes of the metatarsal growth plate (Fig 1h) . This demonstrated that FMOD, and MMP-13 were associated with rudiment cartilage development and bone formation in the metatarsal growth plates. FMOD species were also identified on blots using pAb TsYG11 (Fig 2e) . Very little fragmentation of FMOD was evident in the normal cartilage specimen (Fig 2c) or the finrillated cartilage zones using pAb PR-184 (Fig 2d) . Multiple MMP-13 cleaved FMOD fragments were however evident in the 4 fibrillated cartilage zones examined (Fig 2d) .
Fragmentation of LUM was also evident in the normal and fibrillated cartilage zones using pAb-353 (Fig 2e) . LUM fragmentation was particularly prominent in zone 3 (Fig 2e) .
Histological examination of proteoglycan distribution evident by toluidine blue-fast green staining in normal (Fig 2g) and fibrillated zone 4 (Fig 2j) cartilage regions in the lateral femoral condyles displayed distinct differences. The cartilage thickness was significantly less in the zone 4 specimen and proteoglycan levels severely depleted (compare Fig 2g with 2j) .
Immunolocalisation of FMOD and MMP-13 cleaved FMOD in the same cartilage regions demonstrated that full-length FMOD had a prominent distribution in the superficial cartilage and lower epitope levels deeper in the cartilages (Fig 2h, k) whereas MMP-13 cleaved FMOD was more prominently distributed in both the normal and fibrillated zone 4 (compare Fig 2i   and 2l ). In general FMOD was distributed around the cells presumably associated with collagenous networks in the interstitial matrix. (Fig 3a) . MMP-13 fragmented FMOD species were identified in extracts of normal non-degenerate and degenerate donor cartilages from total knee replacements aged 55, 58, 65, 73, 75 and 83 years of age (Fig 3b) Three prominent FMOD fragments were evident of 54, 45 and 32 kDa in size using the TsYG11 Ab (Fig 3b) however little if any fragmentation was detected using pAb PR-184 however the LUM band instensity was decreased in the older specimens (Fig 3c) . Overnight enzymatic digestions of macroscopically normal articular cartilage from the femoral condyle of a 55 year old male donor using MMP-13, ADAMTS-4 and ADAMTS-5 also generated the three FMOD fragments of similar sizes to those present in Fig 3b (Fig 3d) . These fragments were most prominent in the MMP-13 digests and were present in the tissue residue requiring release by GuHCl extraction as well as being detected in the digestion media.
ADAMTS-4 and ADAMTS-5 also generated FMOD fragments of a similar size and detected using pAb TsYG11 to a lesser extent. Examination of the same digest sample blots with pAb PR-184 again failed to demonstrate FMOD fragmentation (Fig 3e) . MMP-13 digests Stimulation of cultured ovine explants with IL-1α and oncostatin-M resulted in a significant decline in sulfated glycosaminoglycan levels on day 5-12 of culture consistent with the stimulation of aggrecanolysis by this treatment (Fig 6a) . Under the conditions used inclusion of an MMP inhibitor failed to prevent this decline in glycosaminoglycan levels.
Cartilage collagen hydroxyproline values were largely unaffected by the IL-1α/oncostatin-M treatment (Fig 6b) . Immunoblotting of media samples from the explant cultures demonstrated a reduction in FMOD levels on day 12 and the FMOD band was of a lower molecular weight than in control cultures (Fig 6c) . . Glycosaminoglycan (GAG; A) and collagen content (B) of ovine articular cartilage explants after 5 or 12 days of culture in DMEM without (control) or with 5ng/ml IL-1 and 50ng/ml oncostatin M (IL-1/OSM) ± 300nm MMP-inhibitor (expressed as % of the total in explant plus media; mean ± standard deviation). Significant different between control and treated cultures * p<0.05, **p<0.01. (C) Western blot analysis of FMOD core protein and fragments in the cartilage extracts using PR-184 recognising the C-terminus of FMOD.
Discussion
SLRPs have important roles to play in the organisation of the cartilage ECM and functional roles in cartilage development, remodelling and in the pathogenesis of OA [42] . In the present study immunolocalisation of FMOD in the developmental metatarsal and phalangeal rudiment cartilages and metatarsal growth plate of the foot demonstrated FMOD was expressed by normal chondrocytes during cartilage development and by those chondrocytes undergoing hypertrophy in the growth plates. MMP-13 cleaved FMOD was prominent in the growth plates which is consistent with MMP-13 as a marker of hypertrophy and with roles for FMOD and MMP-13 in endochondral ossification. As shown in Figure 1 , the foot has 28 bones and over 30 articulating joints and there are a number of small joints between these bones. These can all be affected by OA, this most commonly affects the hind-foot (sub-talar, talonavicular and calcaneocuboid), mid-foot (metatarsocunieform) and great toe (first metatarsophalangeal) joints.
OA is a progressive degenerative disorder affecting all joint tissues (articular cartilage, meniscus, synovium, subchondral bone, infrapatellar fat pad, ligaments) to variable degree [43, 44] . Historically, degeneration of articular cartilage has been a major focus of studies on the etiopathogenesis of OA. However, with the appreciation of OA as a multifactorial global disorder and that degenerative changes in cartilage are affected by degeneration in the synovium, subchondral bone, infra-patellar fat pad, meniscus, ligaments and tendons [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] there is now a greater appreciation of contributions from all these joint tissues in the achievement of optimal knee functional properties [54] [55] [56] [57] . Results over the last few years have clearly shown that degenerative changes in the menisci, ligaments and tendons can exacerbate degenerative changes in the articular cartilage and may precede these lesions [51] [52] [53] . The innate immune system and inflammation are also now recognized as key pathways in the onset and progression of OA through generation of a variety of damage associated molecular pattern molecules (DAMPs) which act through multiple pathways [58] . DAMPs reside inside the cell or are sequestered in the ECM thus are not normally identified by the innate immune system [59, 60] . In OA however, release of DAMPs from diseased/pathological tissues by proteases [61] [61, 65] . LUM also augments LPS signalling in the innate immune response through interaction with cell surface CD14 (monocyte differentiation factor) which is a coreceptor for bacterial lipopolysaccharide that also interacts with members of the TLR family leading to NFκB activation, cytokine secretion and the inflammatory response [65] . As shown by the findings of the present study, despite similarities in overall structure, FMOD and LUM display differential susceptibilities to degradation by MMPs and ADAMTS-4 and ADAMTS-5. FMOD is susceptible to degradation however LUM is resistant to MMP cleavage, this may be related to its recent identification as an MMP-inhibitor [34] . LUM binds to the catalytic domain of MMP-14 completely inactivating its activity in B16F1 melanoma cells [34] inhibiting the migration of melanoma cells and cell-matrix interactions required to promote tumor progression [30, 67] . This inhibitory activity resides in a peptide named lumcorin located in LRR-9 of LUM [68] . MT1-MMP however cleaves LUM abrogating the suppressive activity it displays towards tumor cell colony formation [69] .
The tyrosine rich residues in the N terminal region of FMOD are sulfated [22] , bind collagen enhancing fibril formation [24] , and heparin binding bioactive factors [24] but are cleaved by MMP-13 [70] . FMOD in articular cartilage, intervertebral disc and meniscus is extensively fragmented in OA [71, 72] and in animal models of IVD and cartilage degeneration [39, 73] . FMOD also contains a number of small KS chains in its central LRR region [74, 75] which are interactive centres for a number of growth factors and morphogens [76] . In a proteomics microarray and plasmon resonance binding study corneal which may modify their interactive properties [78] . Two pattern recognition C-type lectin DAMP receptors, SIGLEC (sialic acid binding Ig-like lectins) [79] and dendritic cell Langerin, identify sialylated KS and galactose-6 sulfate epitopes on KS [80] [81] [82] . Interaction of Langerin with a highly sulfated KS disaccharide has potent anti-inflammatory activity in emphysema and in a model of chronic obstructive pulmonary disease [80] .
In the present study, FMOD was present at a higher density in the superficial region than in the interterritorial matrix of mature knee articular cartilage [83] . MMP-13 cleaved FMOD was also prominent in the deep cartilage regions. FMOD fragmentation has been reported in RA and OA articular cartilage [84, 85] and with ageing [86] . We have recently reported minimal fragmentation of FMOD compared with other SLRPs in osteoarthritic knee menisci and knee and hip articular cartilage when a C-terminal antibody was used for FMOD detection [38] . Results of the present study indicate C-terminal processing of FMOD would have resulted in an inability to detect the processed forms of FMOD using Ab PR-184. Higher levels of FMOD mRNA have been observed in human OA cartilage and increased levels of translated protein indicative of an attempted repair response [84, 85] . FMOD enhances angiogenesis and has critical roles to play in cutaneous wound healing [87] . A deficiency of FMOD leads to delayed wound healing by detrimentally altering temporospatial expression of TGF-β ligands and receptors [87] . LUM also accelerates wound healing by enhancing α2β1 mediated fibroblast contractility at the wound site [88] . TNFαstimulated fibroblasts release elevated levels of LUM at wound sites promoting fibrocyte differentiation upregulating scar formation in healing wounds [89] .
In cartilage degradation in vitro, FMOD is degraded in bovine nasal cartilage explant cultures stimulated with IL-1 [70, 90] . Cleavage in the N-terminal extension of FMOD resulted in release of all but one of its sulfated tyrosine residues [70] . In-vitro experiments demonstrated MMP-13 but not MMP-2,-3,-8, or -9, selectively cleaved at this N-terminal site but only when FMOD was bound to type II collagen and not when in free solution [70] . This work resulted in the development of a neoepitope antibody (TsYG11) to the MMP-13 generated cleavage sequence in bovine FMOD between residues 63 and 64 at PAY and perpetuate a non-infectious inflammatory response alerting the body to tissue injury and contributing to wound healing [95] . Increased expression of DAMPs in OA [96] represent novel therapeutic targets [60] . Furthermore, DAMPs in OA detected by TLR-4 can result in the excitation of nociceptors providing a link between DAMPs and pain pathways [61] . DAMPs are highly variable depending on the cell type and injured tissue [65] . Protein DAMPs include heat-shock proteins , HMGB1 (high-mobility group box 1), and ECM protein fragments generated following tissue injury [97] . [61, 65] . Inhibition of DAMP-mediated inflammatory responses is a promising strategy in the clinical management of OA [94, 95] .
In the present study FMOD fragments in cartilage from total knee replacement tissue donors were compared to FMOD fragments generated by enzymatic digestion of age FMOD is also cleaved by MMP-13, this effect was not observed when a soluble substrate was used but was evident when cartilage pieces were digested. This indicated that the conformation of the FMOD was critical for MMP-13 cleavage with FMOD probably residing on a type I collagen fibre in this study to provide an appropriate orientation for proteolysis.
MMP-13 also cleaves the α1-IX collagen chain which resides on type II collagen fibrils in-situ [99] . This event precedes enzymatic attack of the type II collagen fibre.
To date, a single site has been identified in bovine FMOD that is cleaved by MMP-13, ADAMTS-4 and ADAMTS-5, generating a catabolite approximately 5-10kDa smaller than the full-length protein [70, 91, 92] . Such a naturally-occurring fragment was also identified in OA human knee cartilage. These TsYG11-positive fragments most likely arise from proteolysis at the known MMP-13/ADAMTS cleavage site as well as one of several as yet unidentified cleavage sites in the C-terminus and LRRs. In the present study MMP-13 and ADAMTS-4 generated a significant 37kDa fragment also observed in the OA tissue extracts. This fragment is likely generated by cleavage at the N-terminal site. ADAMTS-4 and 5 have previously been reported to cleave FMOD at the same Tyr-Ala bond as MMP-13, with ADAMTS-5 potentially being more active against FMOD in solution-phase digests [91, 100] .
In contrast, our results demonstrated that ADAMTS-4 showed greater activity against FMOD in cartilage, despite ADAMTS-5 showing superior aggrecanolytic activity in-vitro.
Our data supports previous reports [41, 70] that cleavage of FMOD occurs after the major breakdown of aggrecan but before significant collagenolysis occurs in-vitro, suggesting that removal of FMOD from the collagen fibril may be a prerequisite for collagen proteolysis.
It is interesting that despite the apparent activity of ADAMTS enzymes against FMOD, their increase in early cartilage degradation stimulated by IL-1 [41] or IL-1/OSM in our studies, is apparently not associated with breakdown of this SLRP. It is unclear why cytokine-stimulated ADAMTS activity did not result in more significant FMOD cleavage. It is possible that the concentration of ADAMTS enzymes generated by cytokine-stimulation of chondrocytes may be sub-optimal compared to the levels we used in our in-vitro digests. The living chondrocytes in the cytokine-stimulated culture model better mimics the true in-vivo situation but may secrete other factors in response to cytokine stimulation that abrogate the activity of ADAMTS on FMOD. Thus despite the potential for ADAMTS enzymes, and ADAMTS-4 in particular, to cleave FMOD in cartilage, MMP-13 plays a more significant role in this process, confirming earlier findings with bovine FMOD [70] . Identification of specific fragments of FMOD that are released from cartilage, may provide useful biomarkers to monitor progression of cartilage degradation from early stage aggrecan loss to later collagenolysis and identify therapeutic molecular targets. The differential susceptibility of FMOD and LUM to enzymatic degradation by MMPs observed in the present study was a surprising finding but in keeping with a recent study which demonstrated that LUM was an MMP-14 inhibitor [34] . MMPs are generally considered the physiological modulators of connective tissue composition both in tissue development and in pathological degradation.
However LUM appears to be susceptible either to an MMP other than that examined in this or the cited studies or another class of proteinase. A related SLRP member mimecan/osteoglycan is degraded by BMP-1 which converts it to a form with better interactive properties in collagen fibrillogenesis. A similar proteinase may also be responsible for the LUM fragmentation observed in pathological knee cartilage samples observed in the present study.
Materials and Methods

Consumables
All electrophoresis consumables, pre-poured gels, running buffer concentrates, blotting membranes, pre-stained protein molecular weight standards were obtained from Invitrogen, 
Antibodies
Affinity purified rabbit polyclonal antibodies to the C-terminal peptide sequence LRLASLIEI of human FMOD (Ab PR-184) were used as described earlier [38, 39] . The anti-C terminal LUM antibody used in this study was an affinity purified rabbit polyclonal antibody raised against the peptide sequence H-CGGLRVANEVTLN-OH which comprises an amino terminal cysteine residue used for conjugation to ovalbumin for antibody production, two spacer glycine residues, and the carboxyl terminal 10 amino acids of human, bovine and chick LUM. The anti-LUM antibodies were purified by affinity chromatography using the same immunization peptide as ligand. A rabbit polyclonal antibody (TsYG11) to the ten amino acid linear sequence TYGSPSPPDP C-terminal to the putative MMP-13 cleavage site in human FMOD was generated to examine FMOD core protein fragmentation. Monoclonal antibodies to neoepitope sequences generated by cleavage of aggrecan by ADAMTS (ARGS…; antibody BC- were enzymatically active prior to digestion of cartilage.
Extraction of tissues
Tissues were cut into small pieces using scalpels and extracted with 10 volumes of 4M GuHCl 0.5M sodium acetate pH 5.8 containing 10mM EDTA, 20mM benzamidine and 50mM 6-aminohexanoic acid using end-over end mixing for 48h at 4°C. The tissue residues were separated from the extracts by centrifugation and discarded. Tissue extracts were dialysed against 3 changes of milliQ water and freeze dried.
Chondroitinase ABC, keratanase-I and N-glycanase digestion of tissue extracts
Freeze dried tissue extracts were re-dissolved (2mg dry wt/ml) overnight in 100mM Tris 0.03M acetate buffer pH 6.5 at 4°C with constant end-over-end mixing and aliquots (0.5ml)
were digested with chondroitinase ABC (0.1 U) and keratanase-I (0.05 U) overnight at 37°C.
Selected tissue extracts were also digested with N-glycanase (PNGase F, Glyko laboratories).
Briefly, chondroitinase ABC and keratanase-I digested samples were dialysed and freeze without APMA. After 24h incubation at 37°C, the tissue residues were spun down and the digestion buffer collected. The tissue residues were extracted with 4M GuHCl + proteinase inhibitors (0.5ml) for 48h at 4°C, the extract collected, and the tissue residues discarded.
The 4M GuHCl extracts and digestion buffer samples were dialysed against milliQ distilled water then freeze dried. The samples were reconstituted in 50mM Tris-acetate buffer pH 6.5 (0.2ml) and the glycosaminoglycan (GAG) content of an aliquot was determined using the 1,9-dimethylmethylene blue metachromatic dye binding assay procedure.
Chondroitinase ABC (0.01U/10μg GAG), keratanase-I (0.01 U/10 μg GAG) and keratanase-II (0.1mU/10μg GAG) were added to the samples and they were digested overnight at 37°C. 4X
LDS PAGE application buffer (80μl) + 30μl reducing agent were then added to the digested samples and they were heated on a block at 70°C for 10min. Bentley, WA, Australia). Explants were washed (3 x 5 minutes) in serum free DMEM and cultured individually in serum free DMEM ± 5ng/ml IL-1α plus 50ng/ml oncostatin M (IL-1/OSM; PeproTech Rocky Hill, NJ 08553 , United States) ± 300nm PGE3162689 (synthesized at Procter and Gamble, USA). As previously described, PGE3162689 at this concentration inhibited MMP-1, -2, -3, -7, -8, -9, -13 and -14 but not ADAMTSs in cartilage explant cultures [40] . Explants were cultured for 5 or 12 days with media changed at 5 days (n = 8/treatment/time-point). At harvest, explants (n = 6 / group) were digested with papain, and GAG and hydroxyproline content of the tissue digests and associated media were measured [40] . The remaining two randomly selected explants were pooled and extracted with 4M
GuHCl and the chondroitinase and keratanase digested extracts were analysed by Western 
